橙子视频app安卓下载,91橙子视频,橙子视频旧款,橙子视频在线官网

I-BET762 (GSK525762) is a novel, highly potent, selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family protein BRD4 with an IC₅₀ of ~35 nM. It suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation. It is highly selective over other bromodomain-containing proteins. In vivo studies using I-BET762 have demonstrated efficacy in a range of oncology and immunoinflammatory models. I-BET762 is currently in clinical development for oncology indication. 

How to Use: 

• In vitro:  I-BET762 was used at 0.5-1 µM final concentration in various in vitro assays.
• In vivo: I-BET762 could be dosed to the mice by oral administration at 10-30 mg/kg once per day. 

Reference:

• 1. Mirguet O, et al. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. (2013) J Med Chem. 56(19):7501-15.
• 2. Zhao Y, et al. The making of I-BET762, a BET bromodomain inhibitor now in clinical development. (2013) J Med Chem. 56(19):7498-500. 

Products are for research use only. Not for human use.